Examining underlying transcriptional differences between TA-HECs induced by LTβR agonist treatment alone and in the presence of immune activation (following ICB for example) may shed light on which genes/gene pathways are crucial for generating effective TA-HEVs capable of driving effective anti-tumour immune responses. This evidence concerns the gene LTBR and neoplasm.